Search results for "Cholesterol"

showing 10 items of 1211 documents

Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis o…

2015

Introduction: Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Methods:The searchincludedPUBMED,Cochrane Library,Web ofScience,Scopus,andEMBASE(up toAugust31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weig…

Malemedicine.medical_specialtyCardiotonic AgentsResveratrolCochrane LibraryRisk AssessmentSeverity of Illness IndexGastroenterologyAntioxidantslaw.inventionToxicologychemistry.chemical_compoundRandomized controlled triallawInternal medicineStilbenesHumansMedicineRandomized Controlled Trials as Topicbiologybusiness.industryCholesterolC-reactive proteinPrognosisConfidence intervalSurvival RateC-Reactive ProteinTreatment OutcomeBlood pressurechemistryCardiovascular DiseasesResveratrolMeta-analysisbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses

2013

Objective: Statin pleiotropy is still an evolving concept, and the lack of clarity on this subject is due at least in part to the lack of a definitive biomarker for statin pleiotropy. Using plasma mRNA analysis as a novel research tool for the non-invasive in vivo assessment of gene expression in vascular beds, we hypothesised that atorvastatin lowers the plasmamRNA level from statin pleiotropy-target genes, and the reduction is independent of the reduction of low-density lipoprotein cholesterol (LDL-C). Design and methods: Forty-four patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). Plasma chemokine (C-C motif) ligand 2 (CCL2) and intercellular adhesion molec…

Malemedicine.medical_specialtyChemokineStatinmedicine.drug_classAtorvastatinClinical BiochemistryGene ExpressionDrug Administration ScheduleIn vivoInternal medicineGene expressionAtorvastatinmedicineHumansPyrrolesAngina StableRNA MessengerSerum amyloid AChemokine CCL2AgedbiologyAnticholesteremic AgentsAtorvastatin CCL2 ICAM1 Interventional trial mRNA in plasma Pleiotropic effectsC-reactive proteinCholesterol LDLGeneral MedicineMiddle AgedIntercellular Adhesion Molecule-1EndocrinologyHeptanoic AcidsHMG-CoA reductasebiology.proteinFemalelipids (amino acids peptides and proteins)medicine.drugClinical Biochemistry
researchProduct

Dietary fat interacts with the -514CT polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: th…

2003

We have previously reported an interaction between -514CT polymorphism at the hepatic lipase (HL) gene and dietary fat on high-density lipoprotein-cholesterol (HDL-C) metabolism in a representative sample of white subjects participating in the Framingham Heart Study. Replication of these findings in other populations will provide proof for the relevance and consistency of this marker as a tool for risk assessment and more personalized cardiovascular disease prevention. Therefore, we examined this gene-nutrient interaction in a representative sample of Singaporeans (1324 Chinese, 471 Malays and 375 Asian Indians) whose dietary fat intake was recorded by a validated questionnaire. When no str…

Malemedicine.medical_specialtyChinaGenotypeMedicine (miscellaneous)IndiaBiologyPolymerase Chain ReactionPolymorphism Single Nucleotidechemistry.chemical_compoundFramingham Heart StudyAsian PeopleInternal medicineGenotypeBlood plasmamedicineEthnicityHumansPromoter Regions GeneticTriglyceridesDNA PrimersNutrition and Dieteticsmedicine.diagnostic_testTriglycerideBase SequenceCholesterolConfoundingMalaysiaLipaseDietary FatsEndocrinologychemistryLiverFemaleHepatic lipaseLipid profileThe Journal of nutrition
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease.

2001

Background —Prospective data relating previous exposure to cytomegalovirus (CMV) to the risk of cardiac mortality are controversial. We investigated the effect of previous exposure to CMV infection on the risk of future cardiac disease–related death in relation to an underlying inflammatory response. Methods and Results —Coronary angiography was performed in 1134 subjects, and 989 patients with documented coronary artery disease were studied prospectively. CMV-IgG titers and interleukin (IL)-6 levels were measured before angiography. Increasing titers of CMV correlated with the elevation of IL-6 levels ( P <0.001) after adjustment for possible confounders. All patients were followed up …

Malemedicine.medical_specialtyCongenital cytomegalovirus infectionCoronary DiseaseEnzyme-Linked Immunosorbent AssayAntibodies ViralCoronary AngiographyGastroenterologyRisk AssessmentCoronary artery diseaseBetaherpesvirinaePredictive Value of TestsRisk FactorsPhysiology (medical)Internal medicineGermanymedicineOdds RatioHumansProspective StudiesRisk factorInterleukin 6AgedInflammationmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Cholesterol HDLInterleukinMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisThrombosisSurvival RateC-Reactive ProteinAngiographyImmunologyCytomegalovirus Infectionsbiology.proteinRegression AnalysisFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesCirculation
researchProduct

Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalitie…

2013

BACKGROUND: Therapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore, the objective of this study was to assess the frequency of lipid abnormalities in patients receiving chronic statin treatment. METHODS: As part of an international, cross-sectional, observational study, DYSIS-Middle East enrolled 2,182 patients in the United Arab Emirates (UAE), Saudi Arabia, Lebanon and Jordan. All patients were over 45 years of age and had been on statin treatment for at least …

Malemedicine.medical_specialtyCross-sectional studylcsh:MedicineComorbidityDiseaseMiddle Eastchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusPrevalencemedicineHumanscardiovascular diseaseslcsh:ScienceAgedDyslipidemiasMultidisciplinaryCholesterolbusiness.industrylcsh:Rnutritional and metabolic diseasesMiddle AgedStatin treatmentmedicine.diseaseLipidsComorbidityCross-Sectional StudieschemistryPhysical therapyFemalelcsh:Qlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaResearch ArticleLipoproteinPLoS ONE
researchProduct

Cholesterol levels and risk of hemorrhagic transformation after acute ischemic stroke.

2011

<i>Background:</i> The association between cholesterol levels and hemorrhagic transformation (HT) is still controversial. Studies investigating this issue are influenced by treatments as some are characterized by a higher risk of HT. The aim of our study was to evaluate, in a hospital-based series of patients not treated with thrombolysis, the relationship between cholesterol levels and HT. <i>Methods:</i> We retrospectively collected information about total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) levels at admission in a consecutive series of 240 patients with anterior ischemic stroke (IS). The TC and LDLC levels were arranged in 3 groups acc…

Malemedicine.medical_specialtyDown-RegulationRisk AssessmentBrain Ischemiachemistry.chemical_compoundRisk FactorsCholesterol levels hemorrhagic transformationInternal medicinemedicineOdds RatioHumansRisk factorAcute ischemic strokeAgedRetrospective StudiesChi-Square Distributionbusiness.industryCholesterolCholesterol LDLPrognosisStrokeTransformation (genetics)CholesterolLogistic ModelsNeurologychemistryItalyIschemic strokePhysical therapyCardiologyDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessIntracranial HemorrhagesBiomarkersCerebrovascular diseases (Basel, Switzerland)
researchProduct

Alterations of a Cellular Cholesterol Metabolism Network Are a Molecular Feature of Obesity-Related Type 2 Diabetes and Cardiovascular Disease

2015

Obesity is linked to type 2 diabetes (T2D) and cardiovascular diseases; however, the underlying molecular mechanisms remain unclear. We aimed to identify obesity-associated molecular features that may contribute to obesity-related diseases. Using circulating monocytes from 1,264 Multi-Ethnic Study of Atherosclerosis (MESA) participants, we quantified the transcriptome and epigenome. We discovered that alterations in a network of coexpressed cholesterol metabolism genes are a signature feature of obesity and inflammatory stress. This network included 11 BMI-associated genes related to sterol uptake (↑LDLR, ↓MYLIP), synthesis (↑SCD, FADS1, HMGCS1, FDFT1, SQLE, CYP51A1, SC4MOL), and efflux (↓A…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismGene regulatory networkGene DosageInflammationType 2 diabetesBiologyMedical and Health SciencesTranscriptomeEndocrinology & MetabolismDelta-5 Fatty Acid DesaturaseDiabetes mellitusInternal medicineWeight LossInternal MedicinemedicineHumansObesityGeneAgedRegulation of gene expressionAged 80 and overnutritional and metabolic diseasesEpigenomemedicine.diseaseEndocrinologyCholesterolDiabetes Mellitus Type 2Gene Expression RegulationCardiovascular Diseaseslipids (amino acids peptides and proteins)Femalemedicine.symptomTranscriptomeObesity StudiesDiabetes
researchProduct

Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes

2021

International audience; After an ischemic stroke with evidence of atherosclerosis, lipid-lowering treatment with a target LDL cholesterol of <70 mg/dL compared with 100 ± 10 mg/dL reduced the risk of subsequent cardiovascular events. In this analysis, we explored the effect in the subgroup of patients with diabetes compared with the subgroup without, as well as in those with newly diagnosed diabetes. Patients with ischemic stroke in the previous 3 months or transient ischemic attack within the previous 15 days and evidence of cerebrovascular or coronary artery atherosclerosis were randomly assigned at a 1:1 ratio to a target LDL cholesterol of <70 mg/dL or 100 ± 10 mg/dL using statin or eze…

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]HypercholesterolemiaMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineText miningInternal medicineDiabetes mellitusInternal MedicineMedicineHumansIn patientcardiovascular diseasesAgedIschemic StrokeLdl cholesterolbusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseEzetimibe3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeDiabetes Mellitus Type 2Ischemic strokeCardiologylipids (amino acids peptides and proteins)FemaleHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness030217 neurology & neurosurgery
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct